pharma news today glp-1 obesity drug Many people start and stop GLP-1s. Here's why that may be a bad idea : NPR The GLP-1 Access Gap: Mapping

In April 2024, the Federal Trade Commission announced that it was expanding its campaign against pharmaceutical manufacturers improper or inaccurate listing of patents in the Food and Drug Administrations (FDA) Orange Book, disputing junk patent listings for diabetes, weight loss, asthma, and COPD drugs, including Novo Nordisk Inc.s blockbuster weight-loss drug, Ozempic. If the administration revoked Novos extension, patent protection for semaglutide will expire in 2026 as it is scheduled to do in many other countries

Some report that taking semaglutide before bed may help manage nausea, a common side effect, by allowing them to sleep through the initial hours after injection

Weight Cant Wait: A Guide to Discussing Obesity and Organizing Treatment in the Primary Care Setting

The current evidence base therefore does not support conclusions regarding efficacy in postoperative recovery or complication reduction